• Catapult Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering its Humanized Anti-CCR7 Antibody CAP-100

    Lelystad, The Netherlands, 6 May 2020 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, today announced receiving …

  • Catapult Therapeutics to present new CAP-100 data at the upcoming 24th European Hematological Association meeting in Amsterdam

    Lelystad, The Netherlands, 22 May 2019 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, announced today that …

  • Catapult Therapeutics to present new CAP-100 data at the upcoming American Association for Cancer Research annual meeting

    Lelystad, The Netherlands, 25 January 2019 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, announced today that …

  • Catapult Therapeutics to attend Bio-Europe Spring 2019 in Vienna on March 25–27 for partnering discussions

    Catapult Therapeutics will be attending BIO-Europe Spring 2019 in Vienna on March 25–27 to meet and continue discussions with potential …

  • Dr Wiebe Olijve joins Catapult Therapeutics as a Scientific Advisor

    Lelystad, The Netherlands, May 2017 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, announced today that Dr …

  • Catapult Therapeutics awarded EUR 3 million innovation credit from the Dutch government

    Lelystad, The Netherlands, November 2016 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, announced today that it …